What is SKNV?
Established in 2015, SKNV operates as an FDA-registered 503B outsourcing facility, positioning itself as a critical infrastructure provider within the dermatology sector. The company addresses systemic inefficiencies by bypassing traditional intermediaries, thereby facilitating a direct-to-provider model that ensures cost-effective and timely access to over 120 customized formulations. By maintaining rigorous adherence to Current Good Manufacturing Practices (CGMP), SKNV provides a reliable alternative to standard pharmaceutical procurement, effectively bridging the gap between clinical demand and specialized medication production.
How much funding has SKNV raised?
SKNV has raised a total of $35M across 1 funding round:
Private Equity
$35M
Private Equity (2022): $35M with participation from Accelmed Partners
Key Investors in SKNV
Accelmed Partners
A private equity firm focused on investing in and building companies within the healthcare and medical technology sectors.
What's next for SKNV?
With this major strategic investment, SKNV is well-positioned to accelerate its operational footprint and expand its portfolio of dermatological solutions. The company is expected to leverage this capital to enhance its manufacturing throughput and deepen its integration with healthcare providers nationwide. As the demand for personalized medicine continues to rise, SKNV's focus on eliminating supply chain friction will likely serve as a primary driver for its long-term growth trajectory and market penetration in the competitive pharmaceutical landscape.
See full SKNV company page
